Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.

The University of Oxford’s newly established Institute of Developmental and Regenerative Medicine (IDRM) is a unique flagship institution dedicated to meeting an ambitious challenge. Two thirds of all deaths world-wide are due to non-communicable diseases, many of which are cardiovascular, neurological or immune system disorders that have a developmental origin, representing an urgent unmet clinical need. Professor Paul Riley has been appointed Director of the IDRM to oversee programmes that will lead to the development of new drugs and therapeutic strategies to tackle these chronic illnesses. Notably, this will be brought about through a formal merger of developmental biology and regenerative medicine in the form of 220 world-leading cardiovascular, neuroscience and immunology researchers integrating their expertise to foster multidisciplinary collaborations. Alongside Professor Riley, the primary investigators will be Professor Georg A P Holländer (Hoffmann and Action Medical Research Professor of Paediatrics) and Professor Matthew Wood (Professor of Neuroscience).

The full story is available on the Department of Physiology, Anatomy & Genetics website

Similar stories

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

Daily contact COVID-19 testing for students effective at controlling transmission in schools

A study by the University of Oxford has found that daily testing of secondary school students who were in contact with someone with COVID-19 was just as effective in controlling school transmission as the current 10-day contact isolation policy.